The 2022 AHA/ACC/HFSA Guidelines – Adopting SGLT-2 Inhibitors Across the Spectrum of Heart Failure Shifting the Vernacular of HF: Implications of the 2022 HF Guidelines
The 2022 AHA/ACC/HFSA Guidelines – Adopting SGLT-2 Inhibitors Across the Spectrum of Heart Failure Shifting the Vernacular of HF: Implications of the 2022 HF Guidelines is organized by Projects In Knowledge Inc. (PIK).
Release Date: Mar 24, 2023
Termination Date: Mar 23, 2024
Activity Goal:
The goal of this program is to provide the most current clinical information and practical management strategies for treating heart failure, as seen in clinical practice, in a customized, interactive, and easily digestible on-demand educational program.
Learning Objective(s):
• Apply current guideline recommendations for the classification, staging, and diagnosis of all heart failure (HF) subtypes, including the use of biomarkers.
• Identify key differences in guideline recommendations for the management of different HF subtypes, including those with preserved, mildly reduced, reduced, and improved ejection fraction.
Additional details will be posted as soon as information is available.